

JANSSEN PATIENT ASSISTANCE PROGRAM

FOR INSURED PATIENTS WHO ARE FACING ACCESS AND AFFORDABILITY CHALLENGES

Janssen believes that access and affordability challenges shouldn't stand in the way of patients and their medications. Patient assistance is available if you have commercial, employer-sponsored, or government coverage that does not fully meet your needs. You may be eligible to receive your prescribed Janssen medication free of charge for up to one year. You must meet the eligibility and income requirements for the patient assistance program.

WHAT ARE THE ELIGIBILITY REQUIREMENTS?

Patients may be eligible to receive Janssen medications free of charge for up to one year if they meet the following requirements:

- **You have a commercial or employer-sponsored insurance plan or government coverage, such as Medicare, Medicaid, TRICARE, U.S. Department of Veterans Affairs health care, or U.S. Department of Defense health care**
- **You live in the United States or a U.S. territory**
- **You are treated as an outpatient by a healthcare provider licensed in the U.S.**
- **You have been prescribed an eligible Janssen medication**
- **You meet the income eligibility requirements for your specific Janssen medication(s)**
- **You spend more than 4% of your gross annual household income on prescription drugs***

*Applicable to Medicare Part D Patients only.

WHAT ARE THE INCOME REQUIREMENTS FOR ELIGIBLE MEDICATIONS?

JANSSEN MEDICATION	Income Limit by Household Size		
	1	2	5
AKEEGA ^{™*} (niraparib and abiraterone acetate)	\$81,540	\$109,860	\$194,820
BALVERSA ^{®*} (erdafitinib) Tablets	\$81,540	\$109,860	\$194,820
DARZALEX ^{®*} (daratumumab) Injection for intravenous infusion	\$81,540	\$109,860	\$194,820
DARZALEX FASPRO ^{®*} (daratumumab and hyaluronidase-fihj) Injection for subcutaneous use	\$81,540	\$109,860	\$194,820
EDURANT ^{®*} (rilpivirine) Tablets	\$40,770	\$54,930	\$97,410
ELMIRON ^{®*} (pentosan polysulfate sodium) Capsules	\$40,770	\$54,930	\$97,410
ERLEADA ^{®*} (apalutamide) Tablets	\$81,540	\$109,860	\$194,820
Infliximab , [†] For injection, for intravenous use	\$81,540	\$109,860	\$194,820
INTELENCE ^{®*} (etravirine) Tablets	\$40,770	\$54,930	\$97,410
INVEGA HAFYERA ^{™†} (paliperidone palmitate) Extended-release Injectable Suspension	\$40,770	\$54,930	\$97,410
INVEGA SUSTENNA ^{®†} (paliperidone palmitate) Extended-release Injectable Suspension	\$40,770	\$54,930	\$97,410
INVEGA TRINZA ^{®†} (paliperidone palmitate) Extended-release Injectable Suspension	\$40,770	\$54,930	\$97,410
INVOKAMET ^{®†} (canagliflozin/metformin HCl) Tablets	\$40,770	\$54,930	\$97,410
INVOKAMET XR [†] (canagliflozin/metformin HCl) Extended-release Tablets	\$40,770	\$54,930	\$97,410
INVOKANA ^{®*} (canagliflozin) Tablets	\$40,770	\$54,930	\$97,410
OPSUMIT ^{®†} (macitentan) Tablets	\$81,540	\$109,860	\$194,820
PONVORY ^{®*} (ponesimod) Tablets	\$54,360	\$73,240	\$129,880
PREZCOBIX ^{®*} (darunavir 800mg/cobicistat 150mg) Tablets	\$40,770	\$54,930	\$97,410
PREZISTA ^{®*} (darunavir) Tablets or Oral Suspension	\$40,770	\$54,930	\$97,410
REMICADE ^{®†} (infliximab) Intravenous Infusion	\$81,540	\$109,860	\$194,820
RISPERDAL CONSTA ^{®†} (risperidone) Long-acting Injection	\$40,770	\$54,930	\$97,410
RYBREVA ^{™*} (amivantamab-vmjw) Injection, for intravenous use	\$81,540	\$109,860	\$194,820
SIMPONI ^{®*} (golimumab) Injection	\$81,540	\$109,860	\$194,820
SIMPONI ARIA ^{®†} (golimumab) Intravenous Infusion	\$81,540	\$109,860	\$194,820
SPRAVATO ^{®†} (esketamine) Nasal Spray CIII, for intranasal use	\$40,770	\$54,930	\$97,410
STELARA ^{®*} (ustekinumab) Injection, for intravenous use	\$81,540	\$109,860	\$194,820
STELARA ^{®*} (ustekinumab) Injection, for subcutaneous use	\$81,540	\$109,860	\$194,820
SYMTUZA ^{®†} (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide) Tablets	\$40,770	\$54,930	\$97,410
TALVEY ^{™†} (talquetamab-tgvs) Injection, for subcutaneous use	\$81,540	\$109,860	\$194,820
TECVAYLI ^{®†} (teclistamab) Injection, for subcutaneous use	\$81,540	\$109,860	\$194,820
TRACLEER ^{®†} (bosentan) Tablets	\$81,540	\$109,860	\$194,820
TREMFYA ^{®*} (guselkumab) Prefilled syringe or One-Press patient-controlled injector	\$81,540	\$109,860	\$194,820
UPTRAVI ^{®*} (selexipag) Tablets	\$81,540	\$109,860	\$194,820
VELETRI ^{®*} (epoprostenol) Injection	\$81,540	\$109,860	\$194,820
VENTAVIS ^{®*} (iloprost) Inhalation solution	\$81,540	\$109,860	\$194,820
XARELTO ^{®†} (rivaroxaban) Tablets or Oral Suspension	\$40,770	\$54,930	\$97,410
YONDELIS ^{®*} (trabectedin) Injection for Intravenous Infusion	\$81,540	\$109,860	\$194,820

Please contact us at **1-833-742-0791** for more information about income requirements for households of other sizes.

*Please see Important Safety Information and full Prescribing Information available at <https://www.janssencarepath.com/patient/important-safety-information> and available from your Janssen representative.

†Please see Important Safety Information, including BOXED WARNING, and full Prescribing Information available at www.janssencarepath.com/patient/important-safety-information and available from your Janssen representative.

WHAT ARE THE ENROLLMENT OPTIONS?



ONLINE ENROLLMENT

For Providers

Online at [JanssenPatientAssistance.com/HCP](https://www.JanssenPatientAssistance.com/HCP)

To complete the enrollment on behalf of patient(s), you will need to have the following available:

- Patient eligibility criteria
- Patient information
- Insurance information
- Prescription information
- Patient Authorization or Business Associate Agreement

For Patients and Caregivers

Online at [JanssenPatientAssistance.com](https://www.JanssenPatientAssistance.com)

To complete the enrollment, you will need to have the following available:

- Your insurance information
- Healthcare provider's information
- Prescription Form*

*Important: In order to process your enrollment, your prescription information must be completed on the Patient Assistance Prescription Form and signed by your doctor. This form can be downloaded [here](#) and uploaded during the enrollment process or faxed to 1-833-512-0497.

For Medicare Part D patients only: A spend report or Explanation of Benefits that shows out-of-pocket costs for the current year

**Online enrollment is not available for TALVEY™, TECVAYLI®, SPRAVATO®, ELMIRON®, or Janssen Pulmonary Hypertension medications.*



FAX ENROLLMENT

If you prefer to complete your enrollment offline, follow these steps:

Download a copy of the Patient Enrollment Form by clicking [here](#)

- Patients/caregivers and their healthcare providers will need to complete the form
- Gather supporting document requirements
 - Insurance cards, proof of income, and/or prescription expense reports
- Fax completed form and supporting documents to **1-833-512-0497**

Next Steps: We will determine your insurance coverage, needs, and eligibility to match you with a Janssen program that meets your needs. We will provide update(s) to both patients and their healthcare providers on enrollment status.

GET STARTED TODAY

www.JanssenPatientAssistance.com

Call **1-833-742-0791**

Hours: **Monday through Friday, 8:00 AM - 8:00 PM ET**

WHAT ARE THE TERMS & CONDITIONS?

PATIENT ASSISTANCE PROGRAM

You may be eligible to receive your Janssen medication(s) free of charge for up to one year if you have been prescribed a Janssen medication, have a financial hardship, and are currently enrolled in government, commercial, or employer group health insurance.

You must meet the eligibility and income requirements to qualify for the patient assistance program.

You are not eligible for free Janssen medication if your health insurance will cover the cost of your Janssen-prescribed medication if this application is denied. Some employers, insurers, and other companies force patients to apply for medically necessary medications from free product programs instead of covering such medications directly and immediately through insurance, which could lead to delays in care and discriminate against lower-income patients. These types of "Assistance Diversion Programs" are generally established by companies that profit by diverting resources away from patients in need. An Assistance Diversion Program is any insurer, employer, or third-party program that withholds coverage or payment for Patient's medically necessary drug until Patient has completed an application for free product assistance. Assistance Diversion Programs are prohibited by Janssen to make sure that help is available for patients with no safety net in place. Your insurer must submit a Patient Eligibility Certification form to confirm that your drug coverage is not subject to an Assistance Diversion Program.

You may not seek payment for the value of Janssen medications received from this program from any health plan, patient assistance foundation, flexible spending account, or healthcare savings account.

Before you enroll in the patient assistance program, it is important you understand that you will be asked to provide personal information that may include your name, address, phone number, email address, financial information, and information related to your prescription medication insurance and treatment. This information will be used by Janssen Pharmaceuticals, Inc., and its service providers to determine your eligibility for, enroll you in, and administer the program. The information will also be used to learn more about the people who use the program, to improve the program, and will be shared with service providers supporting the program.

If you have Medicare Prescription Drug Coverage (Part D) you may be asked to attest to or submit a report from your pharmacy or an Explanation of Benefits (EOB) statement from your insurer that shows your out-of-pocket costs for the current year. To qualify for the program, 4% of your gross annual household income must be spent on out-of-pocket prescription expenses for you and/or other members of your household.

This program offer may not be used with any other coupon, discount, prescription savings card, free trial, or other offer. Offer good only in the United States and its territories. Void where prohibited, taxed, or limited by law. Program terms will expire at the end of each calendar year and may change or end without notice, including in specific states.

You may end your participation in the program at any time by calling 833-742-0791, Monday through Friday, 8:00 AM to 8:00 PM ET.

**You may end your participation in the program at any time by calling
1-833-742-0791
Monday through Friday, 8:00 AM – 8:00 PM ET**

